Matches in Nanopublications for { ?s ?p "[The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP321608.RAedPuXt_mYKP8D7fRQfsl5sYJHibBcGJMjBkJcibvjJU130_assertion description "[The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP321608.RAedPuXt_mYKP8D7fRQfsl5sYJHibBcGJMjBkJcibvjJU130_provenance.
- NP578343.RAS9L7iel84R05jCQxFwmXvMxF4N58bpCmVgzcv5O0sDg130_assertion description "[The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP578343.RAS9L7iel84R05jCQxFwmXvMxF4N58bpCmVgzcv5O0sDg130_provenance.
- NP387409.RAhtGyaZCkRDJUiDu_QeE9Od-AnmgrVGKVJdDCXM0NzNQ130_assertion description "[The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP387409.RAhtGyaZCkRDJUiDu_QeE9Od-AnmgrVGKVJdDCXM0NzNQ130_provenance.
- NP420924.RAPqeYq6jlclNPQnMsDJ3GD-4NHZNp2yJgMQv-qcw-eqE130_assertion description "[The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420924.RAPqeYq6jlclNPQnMsDJ3GD-4NHZNp2yJgMQv-qcw-eqE130_provenance.
- NP701575.RAn7bnSQxbq-nyNuD42L1eRJWQjxLwwkk14rj_hQBHtd0130_assertion description "[The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP701575.RAn7bnSQxbq-nyNuD42L1eRJWQjxLwwkk14rj_hQBHtd0130_provenance.
- NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_assertion description "[The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_provenance.
- NP593852.RAxE9TbtwkGHgfc0yA-1INXsSVwhp1rFbDt9HFfl0ABXw130_assertion description "[The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP593852.RAxE9TbtwkGHgfc0yA-1INXsSVwhp1rFbDt9HFfl0ABXw130_provenance.
- assertion description "[The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP852954.RAZaNCs2CG9cvKXFiPzZ_gaKU27Cw5iZte5FLzb01Kz34130_assertion description "[The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP852954.RAZaNCs2CG9cvKXFiPzZ_gaKU27Cw5iZte5FLzb01Kz34130_provenance.